Despite disease-related eye changes, visual acuity — the sharpness of a person’s vision, with 20/20 denoting perfect clarity of sight — was “good” in children and adults with Fabry disease, a study showed. Eye involvement was not associated with disease severity in adults with Fabry, and overall vision-related…
Gene therapy ST-920 (isaralgagene civaparvovec) continues to be effective and well-tolerated in adults with Fabry disease, according to the latest data from an ongoing Phase 1/2 clinical trial that’s testing the experimental treatment. Five of the participants treated with ST-920 the longest — up to 15 months, or…
A man with Fabry disease undergoing long-term dialysis to support kidney function and receiving enzyme replacement therapy (ERT) experienced recurrent complications related to blood vessels in his brain, a case study reported. While further investigation into such cases is needed, the researchers recommended that Fabry patients with end-stage…
The risk of severe COVID-19 in people with Fabry disease appears to be driven by immune system function rather than by the genetic disorder itself — “similar to the general population” — a small study concluded. “Immunosuppression therapy in kidney transplant recipients represented the highest risk in this [patient]…
High levels of calciprotein particles (CPP) — tiny structures that transport excess minerals in the bloodstream — were found in adults with Fabry disease who have a low bone mineral density (BMD), a study revealed for the first time. The hip bone and the top of the upper leg…
A rare case of end-stage kidney disease was discovered in a young boy with Fabry disease, a case study reported. In such cases of unexplained kidney failure in children, a detailed family history should be taken, and Fabry considered a possible cause, the researchers recommended. The case study, “…
Two years of treatment with the experimental enzyme replacement therapy PRX-102 (pegunigalsidase alfa) prevented kidney decline in adults with Fabry disease and showed safety and effectiveness similar to Fabrazyme (agalsidase beta), top-line data from the BALANCE Phase 3 clinical trial show. In addition to meeting the trial’s primary goal…
Sangamo Therapeutics’ gene therapy candidate ST-920 safely and effectively increased and sustained the levels of the alpha-GalA protein, the enzyme that is lacking in people with Fabry disease, according to preliminary Phase 1/2 trial data. Four people have been treated at the first two therapy doses being…
A recent type A meeting with the U.S. Food and Drug Administration (FDA) is likely to lead Protalix Biotherapeutics to resubmit a request for approval of PRX-102 (pegunigalsidase alfa) to treat Fabry disease, after its initial application was rejected by the agency. “We are pleased with the results of the…
Two cases of Fabry disease, diagnosed decades after symptom onset, were identified for the first time in a Central Asian family, a case study reported. Further analysis revealed many affected family members, demonstrating the importance of examining the relatives of people diagnosed with Fabry, the…
Get regular updates to your inbox.